ArticleVaccine2013
Evaluation of immunogenicity and protective efficacy of orally delivered Shigella type III secretion system proteins IpaB and IpaD.
Article in Vaccine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 46 citations in OpenAlex.
- Effects of improved water, sanitation, handwashing, and nutrition on early childhood IgG immune repertoire development againstmSphere · 2026Trial
- Review
- Computational structural dynamics and immunoinformatic analysis of EIEC IpaHMolecular diversity · 2026Article
- Effects of improved water, sanitation, handwashing and nutrition on early childhood IgG immune repertoire development againstmedRxiv : the preprint server for health sciences · 2025Article
- Conserved antigens for enteric vaccines.Vaccine · 2025Review
- A newly developed oral infection mouse model of shigellosis for immunogenicity and protective efficacy studies of a candidate vaccine.Infection and immunity · 2025Article
- Shigella virulence protein VirG is a broadly protective antigen and vaccine candidate.NPJ vaccines · 2024Article
- A broadly immunogenic polyvalentInfection and immunity · 2023Article
- A NovelmSphere · 2023Article
- Systems approach to define humoral correlates of immunity to Shigella.Cell reports · 2022Article
- Characterization of Functional B-Cell Epitopes at the Amino Terminus ofApplied and environmental microbiology · 2022Article
- A Comprehensive Computational Investigation into the Conserved Virulent Proteins ofMolecules (Basel, Switzerland) · 2022Article
- Efficient production of immunologically active Shigella invasion plasmid antigens IpaB and IpaH using a cell-free expression system.Applied microbiology and biotechnology · 2022Article
- An antibody targeting type III secretion system induces broad protection against Salmonella and Shigella infections.PLoS neglected tropical diseases · 2021Article
- TheMicroorganisms · 2021Review
- Repertoire of Naturally Acquired Maternal Antibodies Transferred to Infants for Protection Against Shigellosis.Frontiers in immunology · 2021Article
- SipD and IpaD induce a cross-protection against Shigella and Salmonella infections.PLoS neglected tropical diseases · 2020Article
- Development of a Broadly Protective, Self-Adjuvanting Subunit Vaccine to Prevent Infections byFrontiers in immunology · 2020Article
- In-silico design and production of a novel antigenic chimeric Shigella IpaB fused to C-terminal of Clostridium perfringens enterotoxin.Molecular biology reports · 2019Article
- A Combined YopB and LcrV Subunit Vaccine Elicits Protective Immunity againstJournal of immunology (Baltimore, Md. : 1950) · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
Shigella spp. are food- and water-borne pathogens that cause shigellosis, a severe diarrheal and dysenteric disease that is associated with a high morbidity and mortality in resource-poor countries. No licensed vaccine is available to prevent shigellosis. We have recently demonstrated that Shigella invasion plasmid antigens (Ipas), IpaB and IpaD, which are components of the bacterial type III secretion system (TTSS), can prevent infection in a mouse model of intranasal immunization and lethal pulmonary challenge. Because they are conserved across Shigella spp. and highly immunogenic, these proteins are excellent candidates for a cross-protective vaccine. Ideally, such a vaccine could be administered to humans orally to induce mucosal and systemic immunity. In this study, we investigated the immunogenicity and protective efficacy of Shigella IpaB and IpaD administered orally with a double mutant of the Escherichia coli heat labile toxin (dmLT) as a mucosal adjuvant. We characterized the immune responses induced by oral vs. intranasal immunization and the protective efficacy using a mouse pulmonary infection model. Serum IgG and fecal IgA against IpaB were induced after oral immunization. These responses, however, were lower than those obtained after intranasal immunization despite a 100-fold dosage increase. The level of protection induced by oral immunization with IpaB and IpaD was 40%, while intranasal immunization resulted in 90% protective efficacy. IpaB- and IpaD-specific IgA antibody-secreting cells in the lungs and spleen and T-cell-derived IL-2, IL-5, IL-17 and IL-10 were associated with protection. These results demonstrate the immunogenicity of orally administered IpaB and IpaD and support further studies in humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.